| Methods |
Randomized, parallel, double‐blind, placebo‐
controlled study. |
| Participants |
N= 54;
Geographic region: Sweden
Mean age: not reported
Discontinuations/Not available to follow‐up: 20 dropouts across all groups |
| Interventions |
(a) Allopurinol 300 mg + placebo (n=18)
(b) Allopurinol
300 mg two times daily (n=16)
(c) placebo (n=20).
Study duration: 240 days |
| Outcomes |
Subjective discomfort scale; urate (serum, urine, expressed prostatic secretion), xanthine, leukocyte concentrations. |
| Notes |
Randomization code was centralized but not described. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
